Fig. 2.

Tau/parkin co-expression and effect on dopamine neurons. (A) Parkin immunostaining in substantia nigra 5 weeks after injecting a mixture of tau/parkin AAV. (B) Adjacent section processed for human tau immunostaining. (C) Higher magnification of parkin immunostaining. (D) Higher magnification of tau immunostaining. Arrows point to the same blood vessel in A, B or C, D demonstrating co-expression on adjacent sections. (E) Tyrosine hydroxylase staining in midbrain. The tau/parkin AAV mixture was injected on one side (right side of panel) and the tau/GFP AAV mixture on the other at a total dose of 2 × 10¹⁰ particles in either case 5 weeks earlier. There were more tyrosine hydroxylase-positive neurons on the side of parkin co-expression (see Table 1). Bars, A = 100 μm; C=25 μm; E = 190 μm; A, B same magnification; C, D same magnification.